A Phase 1 Study of AIR-001 in Adults with AATD.

2025-523558-14-00 Protocol AIR-001-AATD-101 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 6 EU/EEA countries · 10 sites · Protocol AIR-001-AATD-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 45
Countries 6
Sites 10

Alpha-1 Antitrypsin Deficiency

Key facts

Sponsor
Airna Corp.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08], Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16], Diseases [C] - Digestive System Diseases [C06]
Decision date (initial)
2026-04-21
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2025-523558-14-00
WHO UTN
U1111-1330-1003

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Alpha-1 Antitrypsin Deficiency

VersionLevelCodeTermSystem organ class
28.0 LLT 10001806 Alpha-1 anti-trypsin deficiency 10010331

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Airna Corp.

Sponsor organisation
Airna Corp.
Address
1 Kendall Square Building 300
City
Cambridge
Postcode
02139-1562
Country
United States

Scientific contact point

Organisation
Airna Corp.
Contact name
Kristina Storey

Public contact point

Organisation
Airna Corp.
Contact name
AiRNA Corporation

Locations

6 EU/EEA countries · 10 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Authorised, recruitment pending 6 4
Ireland Authorised, recruitment pending 1 1
Netherlands Authorised, recruitment pending 2 1
Portugal Authorised, recruitment pending 4 1
Spain Authorised, recruitment pending 4 2
Sweden Authorised, recruitment pending 2 1
Rest of world
Georgia, United Kingdom, Australia, New Zealand
26

Investigational sites

Germany

4 sites · Authorised, recruitment pending
Universitaet Des Saarlandes
Int. Medicine and Pneumology, Kirrberger Strasse 100, 66421, Homburg
Medizinische Hochschule Hannover
Pneumology, Carl-Neuberg-Strasse 1, Gross Buchholz, Hanover
Universitaetsklinikum Tuebingen AöR
Medicine, Otfried-Mueller-Strasse 10, Nordstadt, Tuebingen
Universitaetsklinikum Aachen AöR
Medizinische Klinik Ill, Pauwelsstrasse 30, 52074, Aachen

Ireland

1 site · Authorised, recruitment pending
Beaumont Hospital
Department of Medicine/ RCSI, Beaumont Road, Beaumont, Dublin 9

Netherlands

1 site · Authorised, recruitment pending
Leids Universitair Medisch Centrum (LUMC)
Department of Pulmonology, Albinusdreef 2, 2333 ZA, Leiden

Portugal

1 site · Authorised, recruitment pending
Unidade Local De Saude De Matosinhos E.P.E.
Pneumology, Rua Doutor Eduardo Torres, 4464-513, Senhora Da Hora

Spain

2 sites · Authorised, recruitment pending
Hospital Universitari Vall D Hebron
Respiratory, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Marques De Valdecilla
Pneumology, Avenida Valdecilla Sn, 39008, Santander

Sweden

1 site · Authorised, recruitment pending
Karolinska University Hospital
Centrum för Kliniska Cancerstudier, Halsovagen, Flemingsberg, Huddinge

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-12-17 Sweden Acceptable
2026-04-16
2026-04-17